Analysis reveals the high societal costs of Duchenne muscular dystrophy in Germany, indicating significant economic impacts.
Background/Purpose: Duchenne muscular dystrophy (DMD) is the most common hereditary neuromuscular disease, causing progressive muscle degeneration from early childhood. DMD results in severe disability with mobility loss and premature death. Currently, no causal therapy is available in Germany. This study aimed to determine the societal costs of DMD in Germany in 2022.
No takes yet. Share an insight, caveat, or question.
Hackmann et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: